HIV Drugs Market - Global Industry Analysis, Size, Share, Growth Opportunities, Future Trends, Covid-19 Impact, SWOT Analysis, Competition and Forecasts 2022 to 2030
The global HIV drugs market size was valued at USD 30.89 billion in 2019, and is expected to reach USD 36.495 billion by 2027, and is growing at a CAGR of 3.8% during the forecast period from 2020 to 2027.
HIV Drugs Market Overview:
Acquired immunodeficiency syndrome (AIDS) is considered one of the most severe and chronic diseases caused by the human immunodeficiency virus (HIV). It is a viral infection that is spread through exposure to HIV-infected blood, semen, breast milk, and other infected substances. The prevalence of HIV is soaring at a remarkable rate. According to the World Health Organization (WHO), an estimated 33 million people are currently living with HIV. This has led to growing awareness, which has led to an increase in testing procedures. This has subsequently led to a surge in demand for highly potent HIV drugs to treat and manage the disease.
Rising patient population coupled with new product launches is likely to drive market growth. Significant research and development, promotion of government-run awareness programs, new product launches, and increasing market penetration of major companies in developing regions all contribute to the market growth.
HIV Drugs market size estimates and forecasts are provided in terms of sales volume (K units) and revenue (million USD), with historical and forecast data for the period 2017 to 2030, with 2022 being considered as the base year. This report segments the global HIV Drugs market in detail. Regional market sizes related to products by type, by application, and by player are also delivered. In estimating the size of the market, we took into account the impact of COVID-19 and other global crisis.
The global HIV Drugs market is the professional and accurate study of various business perspectives such as major key players, key geographies, divers, restraints, opportunities, and challenges. This global research report has been aggregated on the basis of various market segments and sub-segments associated with the global market.
Industry News and Key Developments
- In January 2021, ViiV Healthcare received the U.S. FDA approval for Cabenuva, the first and only complete long-acting regimen combination drug for HIV treatment.
- In September 2019, Merck Sharp & Dohme Corp., the subsidiary of Merck & Co., Inc., received the U.S. FDA approval for PIFELTRO and DELSTRIGO combination drugs. These drugs can be used to treat adults with HIV-1.
- In February 2018, Mylan Inc. announced the launch of Efavirenz tablets in the U.S. Efavirenz tablets are the first generic version of Sustiva. This product is given in combination with other antiretroviral agents for the treatment of type 1 HIV infection in adults and pediatric patients.
- In November 2017, ViiV Healthcare received the U.S. FDA approval for Juluca in the U.S. Juluca is a single-dose antiretroviral (ART) regimen that suppresses the viral infection.
Top Key Players include in the HIV Drugs Market are
Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, and others.
The HIV Drugs market research report is categorized based on type, applications and region.
On the Basis of Type:
- Multi-Class Combination Products
- Nucleoside Reverse Transcriptase Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Fusion Inhibitors
- Entry Inhibitors - CCR5 Co-Receptor Antagonist
- HIV Integrase Strand Transfer Inhibitor
On the Basis of Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
On the Basis of Region:
Geographically, the global HIV Drugs market has been analyzed in various regions such as North America, Latin America, Middle East, Asia-Pacific, Africa, Europe, and India. The global HIV Drugs region is dominating this market in the upcoming future.
On the basis of region, the global market can be segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is expected to dominate the forecast period, with a market size of USD 20.27 billion by 2020. The dominance of the region is attributed to the rising prevalence of HIV infection among the U.S. population. According to a 2021 study by the Centers for Disease Control (CDC), approximately 1.2 million people were living with HIV at the end of 2018. Such a high patient population base significantly increases the demand for HIV drugs. Another factor contributing to regional growth is population awareness. Moreover, the presence of key players offering innovative HIV drugs for the treatment of HIV infection will further boost the market growth.
Europe is expected to be the second largest market during the forecast period due to rising HIV infection cases and the presence of a large number of HIV drug companies in the region. Moreover, increasing strategic collaborations among European companies will enhance drug availability, which will support market growth in the region. For example, in July 2020, Theratechnologies Inc.'s European subsidiary Theratechnologies Europe Limited partnered with Loxxess to distribute the antiretroviral drug Trogarzo throughout Europe.
The Asia Pacific market is expected to be the fastest growing market with the highest CAGR during the forecast period owing to the high number of HIV patients in densely populated countries such as China and India. Moreover, growing number of therapeutic programs and surging funding from the private sector and healthcare companies are expected to drive the market. For example, in December 2020, Gilead Sciences, Inc., one of the leading antiretroviral drug companies, announced a $1.4 million grant for its "Gilead Asia Pacific Rainbow Grant Program" in the Asia Pacific region. The program is part of Gilead's initiative to improve public-private partnerships in the Asia-Pacific region to address challenges facing people living with HIV.
Rest of the world, including Latin America, Middle East & Africa, is expected to hold a lower market share due to lack of technologically advanced HIV medicines, poor healthcare standards, and relatively limited healthcare spending. However, these regions have good market growth potential over the forecast period as they host a large number of HIV patients.
Further the regions are divided into countries as follows
- North America
- Rest of North America
- Nordic Countries
- Benelux Union
- The Netherlands
- Rest of Europe
- South Korea
- Southeast Asia
- Rest of Southeast Asia
- Rest of Asia-Pacific
- The Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Rest of Latin America
HIV Drugs Market report scope
CAGR of 3.8% during the forecast period.
Multi-Class Combination Products, Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Entry Inhibitors - CCR5 Co-Receptor Antagonist, HIV Integrase Strand Transfer Inhibitor
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck
Regions and Countries Covered
2017 to 2022
2023 to 2030
The major key questions addressed through this innovative research report:
What are the major challenges in front of the global HIV Drugs market?
Who are the key vendors of the global HIV Drugs market?
What are the leading key industries of the global HIV Drugs market?
Which factors are responsible for driving the global HIV Drugs market?
What are the key outcomes of SWOT and Porter’s five analysis?
What are the major key strategies for enhancing global opportunities?
What are the different effective sales patterns?
What will be the global market size in the forecast period?
Any special requirements about this report, please let us know and we can provide custom report.